Notícias

LLY's oncology revenues rise 11% in the first half of 2026, as newer drugs gain traction and pipeline assets add growth opportunities.

The biotech firm announced plans to raise $2 billion through convertible notes, which could be increased to $2.3 billion.

Stock Market Today: The Dow Jones index falls, but tech futures rally Thursday as Nvidia, Salesforce and CrowdStrike surge on earnings.

The biotech company will sell notes due 2032, with an option to raise an additional $300 million, days after its stock hit a multi-year high

ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major hurdle.

The drugmaker's stock is on a tear, but for investors arriving now, the real question is whether the business can outrun its own premium price.

While the market fixates on the STELARA patent cliff, the rest of the story is being missed. That drug now represents a small fraction of the Innovative Medicine portfolio. The remaining 96% of that business is posting remarkable growth, expanding at over 14.

Daraxonrasib, the pill touted by a former member of Congress and cancer patient as a ‘miracle drug,’ has been granted approval in patients with pancreatic adenocarcinoma.

Moderna stock shed 7% on Wednesday with no company news to blame, reopening a brutal question that its 439% year-to-date rally had been drowning out: what exactly does a $59 billion valuation buy on a revenue base this thin?

MRK hits a 52-week high as positive melanoma data, pipeline progress, new launches and M&A bolster its long-term growth outlook.

The past year's gain was bought with volume and access, and management has already said net price goes lower from here.

Rum Group, Merck, and Newmont shares surged to annual highs amid positive company catalysts, Wall Street optimism, and a rise in gold prices.

The optimism around MRNA began last week after Moderna and partner Merck reported that their personalized cancer vaccine, intismeran, met key goals in a late-stage study for high-risk melanoma.

Gain insight on Moderna, Novo Nordisk and more in the latest Market Talks covering the Health Care sector.

Moderna stock rallies as Wolfe Research upgrades it to "Peer Perform." But is there any further upside left in MRNA shares? Let’s find out!

Merck stock sits near analyst targets that fall short of $200, yet a compressed fall calendar of FDA decisions and a pivotal cancer vaccine readout could force Wall Street to rethink the entire post-KEYTRUDA story.

Two unvaccinated Lancaster County residents have died of measles, Pennsylvania health officials said Tuesday, making them the state’s first disease fatalities in 35 years and the first reported anywhere in the U.S. this year. The national case count is already...

Moderna and Merck’s personalized cancer vaccine could transform cancer treatment and create a multibillion-dollar market, but investors may already be pricing in much of its potential.

Merck shares rose on growing confidence in its cancer pipeline, while Royalty Pharma hit a record high as Ziihera’s FDA approval strengthened its royalty opportunity.

Beyond strong drugs, the stock’s ascent was powered by its notable profitability.

Three catalysts, one reshuffling, and a Fed that refuses to move

Moderna Stock Jumps as Wolfe Upgrade Puts Cancer Pipeline in Spotlight

AbbVie's oncology sales fall 2.4% in Q2 as Imbruvica declines, while Venclexta and newer drugs help offset the pressure.

Strong demand for Kimmtrak is fueling Immunocore's growth, while potential label expansion and late-2026 data could add further upside.

Moderna and Merck’s personalized cancer vaccine could transform cancer treatment and create a multibillion-dollar market, but investors may already be pricing in much of its potential.

Moderna just posted an 11% surge with zero news behind it, while its longtime mRNA peer BioNTech can barely keep pace with the broader biotech sector. Something broke between these two names, and figuring out what it means for your position is more urgent than it looks.

Merck & Co., Inc. (NYSE:MRK) jumped 12.6% to a record $152.20 on August 19 after a pivotal melanoma trial validated intismeran autogene, the individualized mRNA cancer therapy developed with Moderna. In the 1,137-patient Phase 3 INTerpath-001 study, intismeran plus Keytruda produced statistically significant and clinically meaningful improvements in recurrence-free survival and distant-metastasis-free survival compared with […]

Jim Cramer declared the data center trade dead on live television and named the stocks he wants instead, but the rotation he described carries a flaw that Wall Street is quietly ignoring.

Stock futures were rising early Tuesday as the tech sector, and chip stocks in particular, looked set to rebound.

Merck and Moderna just proved their cancer vaccine works, and the ripple effects reach far beyond either company. Five names stand to collect a toll on every single dose manufactured, but not all of them carry the same risk.